All Pathways
Hematology & OncologyEmergency

Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)

Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020): Sickle Cell Patient with Pain → Immediate Triage (ESI-2) → Initial Assessment → Signs of ACS or...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Sickle Cell Patient with Pain

    Patient with known SCD presents with acute pain episode

    1. Action

      Immediate Triage (ESI-2)

      High acuity - target analgesic within 60 minutes

      • Assign ESI-2 triage level
      • Target door-to-analgesia <60 minutes
      • Obtain IV access
      • Check vital signs including SpO2
      1. Action

        Initial Assessment

        Evaluate for complications and pain severity

        • Pain assessment (0-10 scale)
        • Respiratory assessment (ACS screening)
        • Fever evaluation
        • Neurological assessment (stroke screening)
        • Hydration status
        1. Decision

          Signs of ACS or Stroke?

          Screen for life-threatening complications

          • ACS: Chest pain, fever, hypoxia, new infiltrate
          • Stroke: Focal neuro deficits, altered mental status
          • Priapism >4 hours
          • Splenic sequestration (LUQ pain, falling Hgb)
          1. Warning

            Critical Complication

            Immediate specialist consultation

            • ACS: Transfusion, antibiotics, incentive spirometry
            • Stroke: Exchange transfusion, neurology consult
            • Priapism: Urology consult, aspiration
            • Sequestration: Transfusion, possible splenectomy
            1. Outcome

              Admit for Ongoing Management

              Inpatient pain management and monitoring

          2. Action

            Rapid Opioid Analgesia

            IV opioids within 60 minutes of arrival

            • Use patient's individualized pain protocol if available
            • Morphine 0.1-0.15 mg/kg IV or equivalent
            • Hydromorphone 0.015-0.02 mg/kg IV alternative
            • Reassess pain every 15-30 minutes
            • Re-dose opioid every 15-30 min until controlled
            1. Action

              Adjunct Therapies

              Supportive care measures

              • IV fluids: isotonic, avoid overhydration
              • Supplemental O2 if SpO2 <95%
              • Incentive spirometry every 2 hours while awake
              • NSAIDs (ketorolac) if no contraindication
              • Antiemetics as needed
              1. Decision

                Pain Controlled After 2-3 Doses?

                Assess response to initial therapy

                1. Action

                  Escalate Therapy

                  Consider admission and PCA

                  • Admit to hospital
                  • Consider PCA (patient-controlled analgesia)
                  • Hematology consultation
                  • Consider transfusion if Hgb significantly below baseline
                  • Evaluate for underlying infection
                2. Action

                  Consider Discharge

                  If pain controlled and stable

                  • Transition to oral opioids
                  • Ensure adequate supply of pain medications
                  • Hydroxyurea adherence counseling
                  • Follow-up with hematology within 7 days
                  • Return precautions: fever, worsening pain, SOB
                  1. Outcome

                    Discharge Home

                    With oral analgesics and close follow-up

Guideline Source

American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not address pediatric-specific dosing in detail
  • Requires institutional opioid protocols for specific dosing
  • Does not cover gene therapy or curative treatments
  • Acute chest syndrome management is simplified

Contraindicated Populations

pregnancy_third_trimester_without_specialist

Applicable Regions

USEUGlobal

EU: Adapt to local opioid prescribing regulations

US: Follow ASH 2020 guidelines for pain management

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)?

The Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain.

What guideline is the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) based on?

This algorithm is based on American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain (DOI: 10.1182/bloodadvances.2020001851).

What are the limitations of the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020)?

Known limitations include: Does not address pediatric-specific dosing in detail; Requires institutional opioid protocols for specific dosing; Does not cover gene therapy or curative treatments; Acute chest syndrome management is simplified. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Sickle Cell Vaso-Occlusive Crisis Management (ASH 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free